Merck KGaA

Merck is a global science and technology company based in Germany. Co. diversifies its activities into four business divisions: Merck Serono, Consumer Health, Performance Materials and Merck Millipore. The Merck Serono develops, manufactures and markets prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and selected cardiovascular and metabolic diseases. The Consumer Health manufactures and markets over-the-counter drugs addressing health themes such as mobility, women's and children's health, cough and cold. Performance Materials is a specialty chemicals business. The Merck Millipore is the supplier of products and services for the life science industry.
  • Ticker659990
  • ISINDE0006599905
  • SectorPharmaceuticals & Biotechnology
  • CountryGermany

Analysts

Hugo Solvet

MERCK KGAA: Fast moving competition makes it hard to push further avelumab in ovarian cancer | BUY | EUR113

MERCK KGAA - BUY | EUR113(+13%) Fast moving competition makes it hard to push further avelumab in ovarian cancer Avelumab+talazoparib discontinued in 1L ovarian Trial design and fast moving competitive landscape Avelumab will not turn around the HC franchise by itself No impact on our valuation… one last catalyst

Michael Waterhouse

Morningstar | Merck KGaA Posts Solid Fourth Quarter with 2019 Outlook Near Our Estimate

Merck KGaA wrapped up 2018 with results mostly in line with our expectations, including $3.8 billion in EBITDA for the year. Management’s outlook for this year of modestly positive revenue growth and high-single-digit EBITDA growth including modest currency headwinds also mostly matches our forecast. We don’t anticipate a material shift to our fair value estimate as we make a few adjustments to our model, but the potential approval of oral multiple sclerosis medication Mavenclad in the U.S. later this year could spur a modest improvement in our outlook. Following the sale of its consumer heal...

Michael Waterhouse

Merck KGaA Posts Solid Fourth Quarter with 2019 Outlook Near Our Estimate

Merck KGaA wrapped up 2018 with results mostly in line with our expectations, including $3.8 billion in EBITDA for the year. Management’s outlook for this year of modestly positive revenue growth and high-single-digit EBITDA growth including modest currency headwinds also mostly matches our forecast. We don’t anticipate a material shift to our fair value estimate as we make a few adjustments to our model, but the potential approval of oral multiple sclerosis medication Mavenclad in the U.S. late...

Jean-Christophe Dourret

Merck KGaA : Merck- 1 Mar 2019

...

Jean-Christophe Dourret

Merck KGaA : Merck - 1 mar 2019

...

Merck KGaA: Merck KGaA's disposal of consumer health business is credit positive

Comment on credit implications following Merck KGaA's disposal of its consumer health business

Merck & Co., Inc. - June 2017 (LTM): Peer Snapshot

Peer Snapshot:  Merck & Co., Inc. - June 2017 (LTM) 14 September 2017 (in US millions) FYE Dec-15 FYE Dec-16 LTM Jun-17 FYE Dec-15 FYE Dec-16 LTM Jul-17 FYE Dec-15 FYE Dec-16 LTM Jun-17

Merck KGaA: Update to discussion of key credit factors

CORPORATES CREDIT OPINION 11 July 2017 Update RATINGS Merck KGaA Domicile Darmstadt, Germany Long Term Rating Baa1 Type LT Issuer Rating - Fgn Curr Outlook Stable Please see the ratings section at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Knut Slatten 33-1-5330-1077 Vice President [email protected] Yasm

Merck & Co., Inc. - March 2017 (LTM): Peer Snapshot

Peer Snapshot:  Merck & Co., Inc. - March 2017 (LTM) 26 June 2017 (in US millions) FYE Dec-15 FYE Dec-16 LTM Mar-17 FYE Dec-15 FYE Dec-16 LTM Apr-17 FYE Dec-15 FYE Dec-16 LTM Mar-17

Merck KGaA: Key Facts and Statistics - FYE December 2016

CORPORATES ISSUER PROFILE 23 May 2017 TABLE OF CONTENTS Company Overview 1 Business Description 2 Management Strategy 4 Financial Highlights 6 Capital Structure and Debt Maturity 8 Company Management 10 Ownership Structure 11 Subsidiaries 12 Subsidiaries Rated by Moody’s 12 Related Websites and Information

Hugo Solvet

MERCK KGAA: Fast moving competition makes it hard to push further avelumab in ovarian cancer | BUY | EUR113

MERCK KGAA - BUY | EUR113(+13%) Fast moving competition makes it hard to push further avelumab in ovarian cancer Avelumab+talazoparib discontinued in 1L ovarian Trial design and fast moving competitive landscape Avelumab will not turn around the HC franchise by itself No impact on our valuation… one last catalyst

Michael Waterhouse

Morningstar | Merck KGaA Posts Solid Fourth Quarter with 2019 Outlook Near Our Estimate

Merck KGaA wrapped up 2018 with results mostly in line with our expectations, including $3.8 billion in EBITDA for the year. Management’s outlook for this year of modestly positive revenue growth and high-single-digit EBITDA growth including modest currency headwinds also mostly matches our forecast. We don’t anticipate a material shift to our fair value estimate as we make a few adjustments to our model, but the potential approval of oral multiple sclerosis medication Mavenclad in the U.S. later this year could spur a modest improvement in our outlook. Following the sale of its consumer heal...

Michael Waterhouse

Merck KGaA Posts Solid Fourth Quarter with 2019 Outlook Near Our Estimate

Merck KGaA wrapped up 2018 with results mostly in line with our expectations, including $3.8 billion in EBITDA for the year. Management’s outlook for this year of modestly positive revenue growth and high-single-digit EBITDA growth including modest currency headwinds also mostly matches our forecast. We don’t anticipate a material shift to our fair value estimate as we make a few adjustments to our model, but the potential approval of oral multiple sclerosis medication Mavenclad in the U.S. late...

Jean-Christophe Dourret

Merck KGaA : Merck- 1 Mar 2019

...

Jean-Christophe Dourret

Merck KGaA : Merck - 1 mar 2019

...

1 director bought

A director at Merck Kgaa bought 2,000 shares at 89.044EUR and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Ahmed Ben Salem ...
  • Jean-Baptiste Rouphael
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Valentin Pernet
  • Veysel Taze
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 12/14/2018

...

Ahmed Ben Salem ...
  • Jean-Baptiste Rouphael
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Valentin Pernet
  • Veysel Taze
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 14/12/2018

...

Aurelien Sivignon ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Michael Foundoukidis
  • Nicolas David
  • Salma Bouraoui
  • Sven Edelfelt
  • Team Pharma
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 10/26/2018 Date Performance since listing Date Performance since listing

...

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Alfred Glaser
  • Antoine Boivin-Champeaux
  • Baptiste Lebacq
  • Christophe Chaput
  • Delphine Brault
  • Emira Sagaama
  • Fatma Agnès Hamdani
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Jerôme Bodin
  • Léopold Authié
  • Matthias Desmarais
  • Michael Foundoukidis
  • Olfa Taamallah
  • Olivier Lebrun
  • Pierre Tegner
  • Rémi Adam
  • Samantha Jeary
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/26/2018

...

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Alfred Glaser
  • Antoine Boivin-Champeaux
  • Baptiste Lebacq
  • Christophe Chaput
  • Delphine Brault
  • Emira Sagaama
  • Fatma Agnès Hamdani
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Jerôme Bodin
  • Léopold Authié
  • Matthias Desmarais
  • Michael Foundoukidis
  • Olfa Taamallah
  • Olivier Lebrun
  • Pierre Tegner
  • Rémi Adam
  • Samantha Jeary
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 26/10/2018

...

Nurhayati Wan

Merck KGaA

Nurhayati Wan

Merck KGaA

Nurhayati Wan

Merck KGaA

Nurhayati Wan

Merck KGaA

Nurhayati Wan

Merck KGaA

Merck KGAA – Proxinvest Corporate Governance Rating ® : D

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Defensive posture warranted Our outlook for global equity markets remains cautious and we expect additional weakness and consolidation, notwithstanding shorter-term countertrend rallies. Indexes throughout Europe and Asia continue their struggle to gain a firm footing, and, unsurprisingly, the same can be said of broad developed and emerging market indexes (i.e., MSCI EAFE, EM, ACWI, ACWI ex-U.S.) which are all in downtrends or have recently broken down. In light of continued global market weakness, we believe a defensive posture is warranted. In today's report we highlight various ways to ac...

Jérôme VINERIER

Short term view - MERCK KGAA : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at €99.43. Breaking below the support at €85.10 would invalidate the trend.

Jérôme VINERIER

Analyse court terme - MERCK KGAA : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 99,43 €. La rupture du support à 85,10 € invaliderait cette tendance.

Jérôme VINERIER

Analyse court terme - MERCK KGAA : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 92,71 €. La rupture du support à 81,47 € invaliderait cette tendance.

Jérôme VINERIER

Short term view - MERCK KGAA : The background trend is clearly bullish.

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at €92.71. Breaking below the support at €81.47 would invalidate the trend.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch